• Redx to Present at Proactive One2One Virtual Investor Forum

    Read more
  • Redx Presents Encouraging Preclinical Data on the Potential of Porcupine and ROCK Inhibitors to Tackle Cancer-Associated Fibrosis

    Read more
  • Interim Results for the Six Months Ended 31 March 2022

    Read more
  • Redx to Present Preclinical Data on Three Proprietary Compounds at the Extracellular Matrix Pharmacology Congress

    Read more
  • Notice of Interim Results

    Read more
  • Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development

    Read more
  • Redx to Present at Jefferies Global Healthcare Conference in New York

    Read more
  • Notice of Annual General Meeting

    Read more
  • Appointment of Non-Executive Director

    Read more
  • Final Audited Results for the Year Ended 30 September 2021 and Operational Update

    Read more